Morfīna Hidrohlorīds Kalceks (Morphine Hydrochloride Trihydrate)

Morphine hydrochloride is a µ‑opioid receptor agonist. By binding to these receptors in the central nervous system, it inhibits the release of nociceptive neurotransmitters, reduces neuronal excitability, and modulates pain pathways, resulting in effective analgesia.

The specific dose and route are determined by the prescribing clinician based on the patient’s pain intensity, prior opioid exposure, renal and hepatic function, and clinical setting. Dosing is individualized and titrated to effect while monitoring safety.

Safety data are limited; morphine crosses the placenta and is excreted in breast milk, potentially causing respiratory depression in the neonate. Use is generally avoided unless the therapeutic benefit outweighs the risk, and only under specialist guidance.

Submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements) and necessary import documentation.

Compared with opioids such as fentanyl or oxycodone, morphine has a well‑characterised pharmacokinetic profile and a longer duration of action when given intravenously, making it a common choice for epidural analgesia. Potency, side‑effect profile and dosing frequency differ, so clinicians select the agent best suited to the patient’s condition.

Store at controlled room temperature, below 25 °C, in the original packaging. Protect from moisture, light and extreme temperatures. Do not freeze. Keep the container sealed until use to maintain sterility.

The sterile solution is administered by a qualified healthcare professional via epidural, intramuscular or intravenous injection. Dosage and infusion rate are set by the prescriber, and the injection site is prepared according to aseptic technique.

The most critical adverse reactions include respiratory depression, profound hypotension, severe allergic reactions (anaphylaxis) and opioid‑induced sedation. Continuous monitoring of respiratory function and vital signs is essential, especially during initiation or dose escalation.

Patients with known hypersensitivity to morphine or any component of the formulation, those receiving monoamine oxidase inhibitors, individuals with uncontrolled severe asthma, and patients with significant respiratory compromise should not receive morphine unless a specialist determines that benefits outweigh risks.